
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Bearish
3
Neutral
1
Bullish
10
Bearish
35
Neutral
1
Bullish
10
Bearish
32
Neutral
0
Bullish
0
Zydus Wellness Ltd (ZYDUSWELL) is currently trading at 387.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zydus Wellness Limited is an integrated consumer company focused on health and wellness products, headquartered in Ahmedabad, India. Despite facing challenges such as early monsoons and GST 2.0 transitions, Zydus Wellness demonstrated strong resilience in non-seasonal product segments, driving double-digit growth in recent quarters. The acquisition of Comfort Click Limited expanded Zydus Wellness's international presence, particularly in the UK, EU, and USA, and enhanced its digital business platform in the consumer healthcare segment. Zydus has maintained its leadership in brands like Sugar Free, Complan, and Nycil, despite varied economic conditions impacting market segments. The company remains committed to ESG principles, achieving a 6.3% improvement in its total ESG score, and ranks in the 99th percentile among global peers in the food products industry group.
Over the past 52 weeks, Zydus Wellness Ltd has traded between a low of ₹298.60 and a high of ₹530.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zydus Wellness Ltd has a market capitalization of approximately 12,331.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zydus Wellness Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.27 and operates in the FMCG sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
You can buy shares of Zydus Wellness Ltd (ZYDUSWELL) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.
Based on its market capitalization of 12,331.91 Cr, Zydus Wellness Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zydus Wellness Ltd operates in the FMCG sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zydus Wellness Ltd is 51.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Zydus Wellness Ltd pays dividends with a current dividend yield of 0.31%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.
Key risks associated with Zydus Wellness Ltd include sector-specific challenges in the FMCG industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.
FMCG
Food - Processing - Others
12,332 Cr
Low Risk
51.3
41.6
1.7
2.2
530.55
298.60
Sales CAGR
1Y
16.37%
3Y
10.60%
5Y
13.78%
10Y
4.19%
Profit CAGR
1Y
29.97%
3Y
34.06%
5Y
—
10Y
-12.64%
ROE
TTM
4.94%
3Y
5.72%
5Y
5.29%
10Y
5.88%
ROCE
TTM
3.85%
3Y
5.93%
5Y
5.72%
10Y
6.22%
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Market Cap
₹ 12,332 Cr
P/E
51.27
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
LOW MARGIN
Technicals
Bearish
Risk
MODERATE RISK
Financial Results
3 days ago
Publication of Unaudited Financial Results
Zydus Wellness Limited announced the publication of its unaudited financial results for the quarter and nine months ended December 31, 2025, in Financial Express.
Investor Call
3 days ago
Investor Call Audio Recording Announcement
The audio recording of the Investor Call on the unaudited financial results for the quarter and nine months ended December 31, 2025, is now available on the company's website.
Financial Results
4 days ago
Zydus Wellness Q3 FY26 Financial Results
Zydus Wellness reports a significant 113.7% increase in net sales to Rs. 9,633 mn for Q3 FY26, with notable growth across multiple product categories.
Investor Presentation
4 days ago
Zydus Wellness Investor Presentation for Q3 2025
The announcement details the release of an investor presentation on the unaudited financial results for Zydus Wellness for the quarter and nine months ending December 31, 2025.
Financial Results
4 days ago
Unaudited Financial Results for Q3 FY2025
The Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025.
Board Meeting Outcome
4 days ago
Board Meeting Approves Unaudited Financial Results
The Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025.